Skip to content
Tirzepatide Report
Pharmacy guide

Empower Tirzepatide Pharmacy Guide: Injection, ODT and Access

Researched & written by Alan PierceClinical Pharmacology WriterUpdated

FDA warning letter
FDA issued Empower Clinic Services, LLC dba Empower Pharmacy a warning letter in April 2025 (Compounding Pharmacy/Adulterated Drug Products). Read the letter on FDA’s own warning-letter database.

On this page

Empower is a dispensing-pharmacy option to discuss with your prescriber, not an advertised medication-and-doctor membership. Its current weight-management catalog lists tirzepatide/niacinamide injection and tirzepatide orally disintegrating tablets, or ODT. A public patient price is not established.1

Our assessment: this guide is most useful if Empower appears on a proposed prescription or fulfillment plan. The essential questions are which product and facility are involved, what your total quote includes and what clinical care your separate prescriber provides. The injection and ODT listings should not be treated as interchangeable versions of one proven treatment.

Before you decide

DecisionWhat to know
RoleDispensing pharmacy; separate prescriber needed
Injection listingTirzepatide/niacinamide
Oral listingTirzepatide ODT; separate formulation
ODT shipping restrictionCannot ship ODT to CA, WI, IA or MN; other routes differ
Patient priceNo dependable public quote established
Regulatory contextTwo April 2, 2025 letters; distinct named entities
Confirm the exact formulation, dispensing location and prescription quote.

What Empower lists, and what that does not establish

The catalog separates tirzepatide/niacinamide injection from tirzepatide ODT. It also distinguishes patient-specific 503A prescription orders from 503B office-use arrangements. Empower says its medications require a licensed prescriber's prescription.12

The ODT launch page specifically says tirzepatide ODT cannot be shipped to California, Wisconsin, Iowa or Minnesota. That restriction concerns the oral product; it should not be generalized to every Empower injection or facility. Confirm the current route-specific rules for your actual prescription.2

For a patient, the first step is identifying the prescribed product rather than browsing a catalog as if it were an over-the-counter shop. Ask your clinician to explain the route, ingredients and reason for choosing the formulation. A tablet that dissolves in the mouth is not simply an injection without a needle; its formulation, administration and evidence require their own explanation.

Do not assume that an oral compounded product produces the outcomes reported in trials of branded injectable tirzepatide. The compounded tirzepatide guide explains the broader distinction from FDA-approved products. Neither a facility registration nor the presence of the same active-ingredient name establishes approval or clinical equivalence.

Where prescribing ends and dispensing begins

Empower's role is the pharmacy component. Your clinician is responsible for evaluating whether treatment is appropriate and for managing the treatment plan. The pharmacy can answer dispensing questions, but a product listing does not mean that a consultation or continuing medical supervision is included in a medication charge.1

Before the prescription is sent, identify who handles follow-up, refills and questions about symptoms. If a telehealth company is arranging the prescription, keep the clinician's contact details as well as the platform's customer-service address. This avoids making the pharmacy the default destination for a concern that needs medical review.

Also ask which legal entity and physical facility will prepare and dispense the order. A large pharmacy brand can involve more than one facility or legal name. The dispensing label and order confirmation should make the actual source understandable. License and shipping eligibility should be checked for the relevant facility and destination state, not inferred from nationwide marketing.

The April 2025 FDA letters need precise attribution

FDA published separate warning letters dated April 2, 2025 to Empower Clinic Services, LLC dba Empower Pharmacy and Empower Clinic Services, LLC dba Empower Pharma. These are distinct primary documents under the legal names identified in each letter. They deserve review alongside the current pharmacy materials.34

The existence of those letters is not a basis for claiming every current prescription is defective, nor does a current product listing establish that the concerns were resolved. This guide does not establish a closeout, a present enforcement outcome or an independently verified quality judgment about a patient's order.

If the letters affect your decision, ask the pharmacy which entity and facility will serve you and what relevant corrective-action documentation it can provide. Discuss the answer with your prescriber. A dated regulatory document and a company's current explanation are different kinds of information; both should retain their dates and scope.

There is no reliable public patient-price shortcut

The reviewed catalog invites pricing inquiries but does not provide a dependable medication-inclusive monthly patient quote. Clinic purchasing arrangements, a direct pharmacy charge and a telehealth bundle can have different economics. A number quoted by a prescribing service should not automatically be described as Empower's public retail price.1

Request an itemized quote identifying medication, supplies, shipping and any separate clinical fees. Ask what quantity is included, how long the prescription is intended to last and whether a higher prescribed amount changes the next order's cost. The goal is to compare the same prescription and period, not the cheapest-looking vial.

For an approved branded comparison, use our Zepbound cost guide. A compounded quote and a branded pharmacy price require different questions about eligibility, formulation and care. The absence of a public Empower price does not prove it is expensive or inexpensive.

Before a prescription is fulfilled

Obtain the order's cancellation and refund terms before it is prepared. This review does not establish an unconditional patient medication-return guarantee. Ask who to contact if a shipment is delayed, the label differs from the agreed prescription or the package arrives with a concern. Keep the prescription and pharmacy instructions available for those conversations.

If you are comparing pharmacies through different prescribing platforms, our Lavender Sky Health review illustrates why the platform quote and the pharmacy assignment need to be read together. Empower can be one part of a treatment arrangement, but the pharmacy name alone does not tell you the total price, scope of care or suitability of the prescription.

The Strive pharmacy guide discusses a different injection combination and prescription-return policy. The Southend pharmacy guide similarly separates dispensing information from a telehealth platform’s price.

The SmartPharmaRX guide explains another pharmacy’s per-vial quote. Compare the prescribed formulation, quantity and supply period, while keeping the separate clinician’s fees outside the pharmacy-only comparison.

Frequently asked questions

Does Empower prescribe tirzepatide through this catalog?

The reviewed catalog is a pharmacy offering. A licensed prescriber must evaluate you and issue an appropriate prescription.

Is Empower ODT equivalent to injectable Zepbound?

That equivalence is not established. The oral compounded formulation and branded injection require separate evidence.

How much does Empower tirzepatide cost?

A dependable public patient quote is not established. Ask for your complete prescription-specific price.

Are Empower Pharmacy and Empower Pharma the same FDA letter?

No. FDA published separate April 2, 2025 letters under the legal names Empower Clinic Services, LLC dba Empower Pharmacy and dba Empower Pharma.

References(4)

  1. Empower Pharmacy (2026). Weight management. Empower Pharmacy. Read source
  2. Empower Pharmacy (2026). Empower ODT launch and access. Empower Pharmacy. Read source
  3. FDA (2025). Warning letter: Empower Clinic Services, LLC dba Empower Pharmacy, April 2, 2025. FDA. Read source
  4. FDA (2025). Warning letter: Empower Clinic Services, LLC dba Empower Pharma, April 2, 2025. FDA. Read source

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated October 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.